Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.017,91
-1,13%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. AMEX Actinium Pharmaceuticals Inc (ATNM) Actinium Pharmaceuticals Inc (ATNM) Notizie

Actinium Pharmaceuticals Inc

ATNM
6,80
0,24 (3,66%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/4/202414:00PRNUSActinium Highlights Ability of Iomab-B to Overcome High-Risk..
01/4/202414:00PRNUSActinium Announces Iomab-B Phase 3 SIERRA Trial Results..
26/3/202412:18PRNUSActinium Announces Clinical Trial to Study Iomab-ACT..
11/3/202412:30PRNUSActinium Pharmaceuticals Launches Actinium-225 Focused..
26/2/202413:30PRNUSActinium Announces Iomab-B Markedly Increases Long Term..
23/2/202413:30PRNUSActinium Highlights Improved Survival with Iomab-B in TP53..
09/2/202422:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02/2/202423:03EDGAR2Form S-3/A - Registration statement under Securities Act of..
02/1/202413:30PRNUSActinium Announces Acceptance of Five Abstracts for..
29/12/202323:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202314:15PRNUSActinium Announces Iomab-B Produces High Response Rates and..
11/12/202313:45PRNUSActinium's Four Presentations at ASH Highlight the Positive..
08/12/202314:00PRNUSActinium to Highlight Broad Potential of Targeted..
01/12/202323:00EDGAR2Form 8-K - Current report
09/11/202323:05EDGAR2Form DEF 14A - Other definitive proxy statements
06/11/202313:30PRNUSActinium Presents Preclinical Data at SITC Demonstrating..
02/11/202321:15PRNUSActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
02/11/202314:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202314:05PRNUSActinium Announces Oral Presentation at ASH Annual Meeting..
04/10/202313:30PRNUSActinium Announces NIH Grant Extension to Advance Clinical..
27/9/202315:05PRNUSActinium Pharma Highlights Abstract Accepted for Poster..
07/9/202314:40PRNUSActinium Pharma Presents Survival Data from Extended..
31/8/202313:00PRNUSActinium Pharma Highlights Three Abstracts Accepted for..
21/8/202313:00PRNUSActinium Pharma Highlights Abstracts Accepted for Oral and..
14/8/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202315:00EDGAR2Form S-3 - Registration statement under Securities Act of..
24/7/202313:00PRNUSActinium Pharma to Present at the 2nd Annual Targeted..
26/6/202313:00PRNUSSNMMI 2023 Annual Meeting Abstract of the Year Awarded to..
23/6/202314:00PRNUSActinium Pharma Highlights Six Abstracts Accepted for Oral..
16/6/202313:00PRNUSActinium Pharma to Present at the Maxim Healthcare Virtual..
14/6/202313:00PRNUSActinium Pharma to Present at the TD Cowen..
12/6/202313:00PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..
07/6/202313:00PRNUSActinium Pharma Set to Join Russell 2000® and Russell 3000®..
22/5/202313:00PRNUSActinium Pharma Announces Six Abstracts Accepted for Oral..
11/5/202317:18PRNUSActinium Pharma Announces Iomab-B SIERRA Trial Results..
10/5/202313:00PRNUSActinium Pharma to Present at Guggenheim Healthcare Talks..
28/4/202314:00PRNUSActinium Highlights Successful Administration of Targeted..
Apertura: 6,58 Min: 6,485 Max: 6,92
Chiusura: 6,56

La tua Cronologia

AMEX
ATNM
Actinium Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network